NEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Reddit, Inc. (NYSE: RDDT) between October 29, 2024 and May 20, 2025, both dates inclusive (the “Class Period”), of the important August 18, 2025 lead plaintiff deadline. SO WHAT: If you purchased Reddit securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Sarepta Therapeutics, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on August 25, 2025 [1]. Group 1: Class Action Details - Investors who purchased Sarepta securities between June 22, 2023, and June 24, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by August 25, 2025 [3]. - The lawsuit alleges that Sarepta made false and misleading statements regarding the safety and efficacy of its gene therapy product, ELEVIDYS, which is intended for treating Duchenne muscular dystrophy [5]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions, as many firms may not have the necessary experience or resources [4]. - The Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company at the time, and has recovered hundreds of millions of dollars for investors [4]. Group 3: Case Specifics - The lawsuit claims that Sarepta failed to disclose significant safety risks associated with ELEVIDYS, which led to adverse events that could impact the therapy's approval and recruitment in clinical trials [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased DoubleVerify Holdings, Inc. common stock during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought DoubleVerify common stock between November 10, 2023, and February 27, 2025, may be eligible for compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by July 21, 2025 [3]. - Investors can join the class action by visiting the provided link or contacting the law firm directly for more information [6]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting their own success in recovering significant amounts for investors [4]. - The firm has been recognized for its leadership in securities class action settlements, achieving the largest settlement against a Chinese company at the time and securing over $438 million for investors in 2019 alone [4]. Group 3: Allegations Against DoubleVerify - The lawsuit alleges that DoubleVerify made false and misleading statements regarding its business operations, including the shift of customer ad spending to closed platforms where its capabilities were limited [5]. - It is claimed that DoubleVerify's high-margin advertising optimization services faced significant challenges in monetization due to the high costs and time required for technology development on closed platforms [5]. - The lawsuit also points out that DoubleVerify overbilled customers for ad impressions served to bots and that its risk disclosures were misleading, leading to investor damages when the true situation was revealed [5].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Elevance Health, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The Class Period for the Elevance Health, Inc. stock purchase is from April 18, 2024, to October 16, 2024 [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A lead plaintiff must file a motion with the Court by July 11, 2025, to represent other class members in the litigation [2]. Group 2: Legal Representation - Investors are encouraged to select qualified legal counsel with a proven track record in securities class actions [3]. - Rosen Law Firm has a history of successful settlements, including the largest securities class action settlement against a Chinese company at the time [3]. - The firm has consistently ranked in the top for securities class action settlements and has recovered hundreds of millions of dollars for investors [3]. Group 3: Case Allegations - The lawsuit alleges that Elevance Health made false or misleading statements regarding the Medicaid redetermination process and its impact on financial guidance [4]. - It is claimed that the acuity and utilization of Medicaid members increased significantly, contrary to the company's assurances to investors [4]. - The misrepresentation of the situation led to investor damages when the true details became public [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Fortrea Holdings, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on August 1, 2025, and the potential for compensation through a contingency fee arrangement [1][2]. Group 1: Class Action Details - Investors who bought Fortrea securities between July 3, 2023, and February 28, 2025, may be eligible to join a class action lawsuit without upfront costs [1][2]. - A class action lawsuit has already been filed, and interested parties must act by the lead plaintiff deadline to represent other class members [2][6]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. Group 3: Allegations Against Fortrea - The lawsuit alleges that Fortrea made false and misleading statements regarding its revenue projections and cost savings, leading to inflated EBITDA targets for 2025 [4]. - The claims suggest that Fortrea's business model and financial prospects were overstated, resulting in investor damages when the true information became public [4].

Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Hims & Hers Health, Inc. common stock during the specified Class Period, indicating potential legal issues surrounding the company's disclosures and partnerships [1][5]. Group 1: Class Action Details - The class action lawsuit is filed for purchasers of Hims common stock between April 29, 2025, and June 23, 2025, inclusive [1]. - Investors who purchased Hims stock during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested parties can join the class action by submitting a form or contacting the law firm directly [3][6]. Group 2: Allegations Against Hims - The lawsuit alleges that Hims made false and misleading statements regarding its partnership with Novo Nordisk A/S, particularly about the availability of the weight-loss drug Wegovy for Hims subscribers [5]. - Specific claims include that Hims failed to disclose the nature of its collaboration with Novo, which was supposed to ensure continued access to Wegovy, and that positive statements were made about the partnership that misled investors [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest securities class action settlement against a Chinese company at the time [4]. - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Fortrea Holdings, Inc. securities during the specified Class Period of the upcoming lead plaintiff deadline on August 1, 2025, and the potential for compensation without out-of-pocket costs [1][2]. Group 1: Class Action Details - Investors who bought Fortrea securities between July 3, 2023, and February 28, 2025, may be eligible to join a class action lawsuit [1][2]. - A class action lawsuit has already been filed, and interested parties must act by the lead plaintiff deadline to represent other class members [2][6]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [3]. Group 3: Allegations Against Fortrea - The lawsuit alleges that Fortrea made false and misleading statements regarding its revenue projections and cost savings, leading to inflated EBITDA targets for 2025 [4]. - The claims suggest that Fortrea's business model and financial prospects were overstated, resulting in investor damages when the true information became public [4].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Organon & Co. securities during the specified class period of the upcoming lead plaintiff deadline for a class action lawsuit [1][2]. Group 1: Class Action Details - The class period for the Organon securities lawsuit is from October 31, 2024, to April 30, 2025, inclusive [1]. - Investors may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A lead plaintiff must file a motion with the court by July 22, 2025, to represent other class members [2]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time [3]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of settlements in 2017 and has consistently ranked in the top 4 since 2013 [3]. - In 2019, the firm secured over $438 million for investors [3]. Group 3: Case Allegations - The lawsuit alleges that Organon's defendants made misleading statements while concealing material adverse facts about the company's capital allocation priorities [4]. - Specifically, the lawsuit claims that the defendants concealed the importance of debt reduction following the acquisition of Dermavant, which led to a 70% decrease in the regular quarterly dividend [4]. - Investors reportedly suffered damages when the true details about the company's financial priorities became public [4].

Core Viewpoint - A class action lawsuit has been filed against Sarepta Therapeutics, Inc. for misleading statements regarding the safety and efficacy of its gene therapy product, ELEVIDYS, during the specified Class Period [1][5]. Group 1: Lawsuit Details - The class action lawsuit is on behalf of purchasers of Sarepta securities between June 22, 2023, and June 24, 2025 [1]. - The lawsuit alleges that Sarepta made false and misleading statements about ELEVIDYS, which is intended for patients with Duchenne muscular dystrophy, including significant safety risks and failure to detect severe side effects [5]. - The lawsuit claims that the adverse events from ELEVIDYS treatment led to a halt in recruitment and dosing in trials, attracting regulatory scrutiny and increasing risks around the therapy's approvals [5]. Group 2: Investor Information - Investors who purchased Sarepta securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - Interested investors can join the class action by visiting the provided link or contacting the law firm for more information [3][6]. - A lead plaintiff must be appointed by August 25, 2025, to represent the class in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements and recognition in the field [4]. - The firm has recovered hundreds of millions of dollars for investors, with over $438 million secured in 2019 alone [4].

NEW YORK, June 27, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of 3D Systems Corporation (NYSE: DDD) between August 13, 2024 and May 12, 2025, both dates inclusive (the “Class Period”), of the important August 12, 2025 lead plaintiff deadline. SO WHAT: If you purchased 3D Systems securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. ...